Letrozole 2.5 - Prime Pharma

Letrozole, marketed as Femara, is a non-steroidal aromatase inhibitor developed by Novartis and approved in 1997. It lowers estrogen levels by blocking aromatase enzyme activity, proving effective in treating estrogen-responsive breast cancer in postmenopausal women. Among bodybuilders, it is utilized to reduce estrogenic effects from anabolic steroid cycles. Despite its potent anti-estrogenic effects, letrozole may cause side effects like bone density reduction, mood changes, and increased cardiovascular risks during extended use .

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Letrozole 2.5 by Prime Pharma, consult with your doctor or healthcare professional.